

NOW ENROLLING

Clinical Trial in People With Stiff Person Syndrome (SPS)

A Phase 2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in People With Treatment Refractory SPS



What is SPS?

SPS is an autoimmune neurological disorder that can affect nerves in the body. In SPS, the braking system of the nerves fails. Symptoms of SPS include stiffness, spasms, pain, and may include unsteady walking and falls.



Traditional treatments:

- 1 Treat symptoms, like muscle relaxers
- 2 Treat pain, like over the counter pain relievers
- 3 Treat the immune system, like IVIg (intravenous immunoglobulin)


The goal of treatment is to reduce spasms, stiffness, and pain. Your doctor can discuss with you the variety of treatment options for SPS, including the benefits and risks of such options.



What is CAR T-cell therapy?

KYV-101 is an investigational CAR T-cell therapy used in over 50 patients. KYV-101 works with your immune system to target the cells that harm your body, including unhealthy B cells that may contribute to disease activity in SPS.

This is the first study using KYV-101 in SPS, but several patients with SPS have been treated with KYV-101. Patients with Lupus Nephritis, Myasthenia Gravis, Systemic Sclerosis (Scleroderma), and Multiple Sclerosis have also been treated with KYV-101.



About KYSA-8

The KYSA-8 trial is designed to evaluate if KYV-101 CAR T-cell therapy is effective and safe in people with SPS who have failed to improve with current medications.

KYSA-8 Principal Investigators



Amanda Piquet, MD

Director, Autoimmune Neurology
University of Colorado School of Medicine
Anschutz Medical Campus, CO



Marinos Dalakas, MD

Director, Neuromuscular Division
Thomas Jefferson University
School of Medicine, PA



Anastasia Zekeridou, MD, PhD

Co-Director Neuroimmunology Laboratory
Associate Professor of Neurology
Mayo Clinic, Rochester, MN



KYV-101 is an investigational therapy.

To learn more about this trial:

Visit: stiffpersonsyndrometrials.com

Email: ClinicalTrialsInfo@kyvernatx.com



What will the **KYSA-8** study involve?




SCREENING

You will undergo assessments with your doctors who will confirm whether you are eligible.



COLLECTING T CELLS

Giving blood to collect your T cells.
Lasts 2-3 hours.




PREPARATION OF CAR T CELLS

Your T cells will be made into KYV-101 CAR T cells to recognize and remove B cells.



PREPARATION FOR TREATMENT

About 1 week before KYV-101 infusion, you will receive treatment to help prepare the immune system.



KYV-101 INFUSION

**The KYV-101
CAR T cells are
returned to your
body via infusion.**




HOSPITAL MONITORING

Beginning with KYV-101 infusion, you will be required to stay in the hospital at the trial site for 10 days so doctors can check how well you are responding to treatment, monitor any potential side effects, and treat their symptoms to help prevent worsening.

CAR T-cell therapies can be associated with Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which may be potentially serious or life-threatening but generally resolve within the first month after treatment.

- Symptoms of CRS include fever, nausea, feeling tired (fatigue), and body aches and can progress in severity and may include low blood pressure, high fever, shock, and potentially organ failure.
- Symptoms of ICANS include fatigue, uncontrolled movements (tremors), impairment in thinking, loss of speech, muscle weakness, or more severe symptoms such as seizures and swelling in the brain.



FOLLOW-UP PERIOD

Follow-up visits to monitor your health will be performed after KYV-101 infusion.



To learn more about this trial:

Visit: stiffpersonsyndrometrials.com

Email: ClinicalTrialsInfo@kyvernatx.com



KYV-101 is an investigational therapy.

Copyright © 2024 Kyverna Therapeutics, Inc. 241213-XK-0038